Journal article
Delivery of Cell-Specific Aptamers to the Arterial Wall with an Occlusion Perfusion Catheter
Molecular therapy. Nucleic acids, Vol.16, pp.360-366
06/07/2019
DOI: 10.1016/j.omtn.2019.03.005
PMCID: PMC6462795
PMID: 30986697
Abstract
Current strategies to prevent restenosis following endovascular treatment include the local delivery of anti-proliferative agents to inhibit vascular smooth muscle cell (VSMC) proliferation and migration. These agents, not specific to VSMCs, are deposited on the luminal surface and therefore target endothelial cells and delay vascular healing. Cell-targeted therapies, (e.g., RNA aptamers), can potentially overcome these safety concerns by specifically binding to VSMC and inhibiting proliferation and migration. The purpose of this study was to therefore demonstrate the ability of a perfusion catheter to deliver cell-specific RNA aptamer inhibitors directly to the vessel wall. RNA aptamers specific to VSMCs were developed using an in vitro cell-based systematic evolution of ligand by exponential enrichment selection process. Two aptamers (Apt01 and Apt14) were evaluated ex vivo using harvested pig arteries in a pulsatile flow bioreactor. Local drug delivery of the aptamers into the medial wall was accomplished using a novel perfusion catheter. We demonstrated the feasibility to deliver aptamer-based drugs directly to the medial layer of an artery using a perfusion catheter. Such cell-specific targeted therapeutic drugs provide a potentially safer and more effective treatment option for patients with vascular disease.
Details
- Title: Subtitle
- Delivery of Cell-Specific Aptamers to the Arterial Wall with an Occlusion Perfusion Catheter
- Creators
- Ofonime Udofot - University of IowaLi-Hsien Lin - University of IowaWilliam H. Thiel - University of IowaMegan Erwin - University of South AlabamaEmily Turner - University of South AlabamaFrancis J. Miller - United States Department of Veterans AffairsPaloma H. Giangrande - University of IowaSaami K. Yazdani - University of South Alabama
- Resource Type
- Journal article
- Publication Details
- Molecular therapy. Nucleic acids, Vol.16, pp.360-366
- DOI
- 10.1016/j.omtn.2019.03.005
- PMID
- 30986697
- PMCID
- PMC6462795
- NLM abbreviation
- Mol Ther Nucleic Acids
- ISSN
- 2162-2531
- eISSN
- 2162-2531
- Publisher
- Elsevier
- Number of pages
- 7
- Grant note
- University of Iowa Award from The Office of the Vice President for Research and Economic Development (OVPRED 2015) I01BX001729 / Veterans Affairs; US Department of Veterans Affairs 2I01BX001729 / Office of Research and Development, Department of Veterans Affairs; US Department of Veterans Affairs R01CA138503; R21DE019953; HL130039; 1R15HL127596 / NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA T32HL007121-41 / NIH training grant; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA 9033-12; 001-09 / Mary Kay Foundation E2766 / Elsa U. Pardee Foundation University of Iowa Department of Internal Medicine University of Iowa Carver College of Medicine (CCOM) (Carver Collaborative Pilot Grant Award 2015) RJCCT 01-224 / Roy J. Carver Charitable Trust R01HL130039 / NATIONAL HEART, LUNG, AND BLOOD INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI) 14SDG18850071; 15SDG25880000; 16PRE27350003 / American Heart Association
- Language
- English
- Date published
- 06/07/2019
- Academic Unit
- Cardiovascular Medicine; Radiation Oncology; Internal Medicine
- Record Identifier
- 9984360045602771
Metrics
68 Record Views